Evidence map›Paper›PMID 28765196›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2017

Ester Borras, Kyle Chang, Mala Pande, Amanda Cuddy, Jennifer L Bosch, Sarah A Bannon, Maureen E Mork, Miguel A Rodriguez-Bigas, Melissa W Taggart, Patrick M Lynch and 2 more

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. What Should a Clinical Cardiologist Know About Cardiogenetics?Journal of the American Heart Association · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ester BorrasDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kyle ChangDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mala PandeDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amanda CuddyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jennifer L BoschDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sarah A BannonClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maureen E MorkClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Miguel A Rodriguez-BigasClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Melissa W TaggartDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick M LynchDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Y Nancy YouClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eduardo VilarDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. EVilar@mdanderson.org.

Funding

R25 SUPPLEMENT IN GENETIC EPIDEMIOLOGY EDUCATIONR25CA057730 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 1992 to 2016
$18.6M
CANCER PREVENTION EDUCAT--STUDENT RESEARCH EXPERIENCESR25CA056452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Shine Chang · 1992 to 2026
$6.9M
Susceptibility Markers for a Breast-Colon Cancer PhenotypeK07CA160753 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PANDE, MALA · 2012 to 2016
$603k
NCI NIH HHS K07 CA160753NCI NIH HHS R25 CA056452NCI NIH HHS R25 CA057730
6 · The paper itself

Abstract

Lynch syndrome (LS) is a genetic condition secondary to germline alterations in the DNA mismatch repair (MMR) genes with 30% of changes being variants of uncertain significance (VUS). Our aim was to perform an

Indexed as

Computer SimulationGenetic VariationAdolescentAdultAgedCohort StudiesColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsDNA Mismatch RepairFemaleHumansMaleMiddle AgedYoung AdultDNA-Binding Proteins

Identifiers

PMID28765196
PMCPMC5626617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.